Literature DB >> 8328379

Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics.

R R Williams1, S C Hunt, M C Schumacher, R A Hegele, M F Leppert, E H Ludwig, P N Hopkins.   

Abstract

Heterozygous familial hypercholesterolemia (FH) is a serious disorder causing twice normal low-density lipoprotein cholesterol levels early in childhood and very early coronary disease in both men and women. Treatment with multiple medications and diet can normalize cholesterol levels in many persons with FH and prevent or delay the development of coronary atherosclerosis. Thus, there is a need for accurate and genetically validated criteria for the early diagnosis of heterozygous FH. Previously published blood cholesterol criteria greatly underdiagnosed new cases of FH among members of known families with FH in Utah and overdiagnosed FH among participants of general population screening, revealing the need for different cholesterol screening criteria in persons from these 2 different settings. The statistical concept of a priori probabilities was applied to derive 2 sets of practical screening criteria: one for persons participating in general population screening studies and another for close relatives of confirmed FH cases, showing dramatic differences. At a cholesterol level of 310 mg/dl, only 4% of persons in the general population would have FH but 95% of persons who were first-degree relatives of known cases would have FH. Detailed tables were derived to provide practical total and low-density lipoprotein blood cholesterol screening criteria for diagnosing FH in different screening settings and specific age groups. In population screening the new FH criteria require a total cholesterol > 360 mg/dl for age 40+ (or 270 mg/dl in youth). Among first-degree relatives of confirmed cases in families with FH, the new total cholesterol criteria are much lower (> 290 mg/dl for age 40+, > 220 mg/dl for youth).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8328379     DOI: 10.1016/0002-9149(93)90155-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  100 in total

Review 1.  Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism.

Authors:  R A Hegele
Journal:  Am J Hum Genet       Date:  2001-10-26       Impact factor: 11.025

2.  Family-specific aggregation of lipid GWAS variants confers the susceptibility to familial hypercholesterolemia in a large Austrian family.

Authors:  Elina Nikkola; Arthur Ko; Marcus Alvarez; Rita M Cantor; Kristina Garske; Elliot Kim; Stephanie Gee; Alejandra Rodriguez; Reinhard Muxel; Niina Matikainen; Sanni Söderlund; Mahdi M Motazacker; Jan Borén; Claudia Lamina; Florian Kronenberg; Wolfgang J Schneider; Aarno Palotie; Markku Laakso; Marja-Riitta Taskinen; Päivi Pajukanta
Journal:  Atherosclerosis       Date:  2017-07-22       Impact factor: 5.162

Review 3.  Role of lipid-lowering pharmacotherapy in children.

Authors:  S Tonstad
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

4.  Detection of subclinical atherosclerosis by electron beam tomography in females with heterozygous familial hypercholesterolaemia.

Authors:  R D Santos; R S Meneghelo; A P M Chacra; T L R Martinez; J A Ramires; J A M Carvalho
Journal:  Heart       Date:  2004-01       Impact factor: 5.994

5.  Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype.

Authors:  Amanda M Perak; Hongyan Ning; Sarah D de Ferranti; Holly C Gooding; John T Wilkins; Donald M Lloyd-Jones
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

6.  What Is Familial Hypercholesterolemia, and Why Does It Matter?

Authors:  Amit V Khera; Robert A Hegele
Journal:  Circulation       Date:  2020-06-01       Impact factor: 29.690

Review 7.  Familial hypercholesterolemia.

Authors:  Victoria Enchia Bouhairie; Anne Carol Goldberg
Journal:  Cardiol Clin       Date:  2015-05       Impact factor: 2.213

8.  SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia.

Authors:  Paulo Caleb Junior Lima Santos; Ana Carolina Moron Gagliardi; Márcio Hiroshi Miname; Ana Paula Chacra; Raul Dias Santos; Jose Eduardo Krieger; Alexandre Costa Pereira
Journal:  Eur J Clin Pharmacol       Date:  2011-09-18       Impact factor: 2.953

9.  A model of care for familial hypercholesterolaemia: key role for clinical biochemistry.

Authors:  Gerald F Watts; David R Sullivan; Frank M van Bockxmeer; Nicola Poplawski; Ian Hamilton-Craig; Peter M Clifton; Richard C O'Brien; Peter M George; John R Burnett
Journal:  Clin Biochem Rev       Date:  2012-02

10.  Identifying Familial Hypercholesterolemia Using a Blood Donor Screening Program With More Than 1 Million Volunteer Donors.

Authors:  Candace L Jackson; James Z Keeton; Stephen J Eason; Zahid A Ahmad; Colby R Ayers; M Odette Gore; Darren K McGuire; Merlyn H Sayers; Amit Khera
Journal:  JAMA Cardiol       Date:  2019-07-01       Impact factor: 14.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.